摘要
目的探讨重组人成骨生长肽(recombinanthumanosteogenicgrowthpeptide,rhOGP)对去卵巢大鼠骨质疏松的治疗作用。方法通过切除大鼠卵巢建立骨质疏松模型,经rhOGP治疗12周后,测定骨密度(BMD)、血清中的酸性磷酸酶(TRAP)、碱性磷酸酶(ALP)和骨钙素(BGP)。结果rhOGP治疗组碱性磷酸酶(233.77±42.07)U/L、骨钙素(1.95±0.15)μg/L和骨密度明显高于骨质疏松模型组(156.23±23.38)U/L、(1.33±0.24)μg/L(P<0.01),而酸性磷酸酶(19.27±4.24)U/L,明显低于骨质疏松模型组(29.98±3.08)U/L(P<0.05)。结论rhOGP能刺激成骨细胞的活性,增加骨密度,提高骨量,对去卵巢大鼠所引起的骨质疏松有效,有可能成为治疗骨质疏松症的有效药物。
Objective To study the anti-osteoporotic effect of recombinant human osteogenic growth peptide(rhQGP) on ovariectomized female rats. Methods Osteoporotic models of rats were duplicated by ovariectomy. Rats in therapeutic groups were administered rhOGP. After a period of 12 weeks, BMD, TRAP, ALP and BGP were assayed. Results The results showed that the level of serum ALP(233.77±42.07)U/L, BGP (1.95±0.15)μg/L and BMD in rhOGP groups were significantly increased (P < 0.01) compared with the osteoporosis control group. Meanwhile, the level of blood TRAP(19.27±4.24)U/L was greatly decreased compared with the osteoporosis control group (29.98±3.08)U/L (P < 0.05). Conclusions rhOGP can stimulate osteoblast activity, promote bone mass effect and improve osteoporosis in ovariect omized female rats. So rhOGP has a potential role in osteoporosis therapy.
出处
《中国地方病学杂志》
CAS
CSCD
北大核心
2004年第4期318-320,共3页
Chinese Jouranl of Endemiology
基金
国家自然科学基金资助项目(39980004)
黑龙江省卫生厅基金资助项目(2003096)
